Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Mar 28, 2013, we reaffirmed our long-term Neutral recommendation on MWI Veterinary Supply (MWIV - Analyst Report) following the strong first-quarter fiscal 2013 results. This leading distributor of animal health products carries a Zacks Rank #3 (Hold).

Why Neutral?

On Feb 4, 2013, MWI Vet reported robust double-digit growth to begin fiscal 2013 on a positive note. EPS rose 25.7% year-over-year to $1.32, reflecting a beat of 10.9% over the Zacks Consensus Estimate.

MWI Vet is witnessing growth across all regions and product categories. As a result, revenues increased 24% year over year to $572.8 million in the quarter, easily surpassing the Zacks Consensus Estimate of $532 million. On an organic basis, domestic growth was 16.6%, whereas sales growth in U.K. was 22%.

MWI Vet’s strategic approach to support growth momentum is yielding positive results. Its costs saving initiatives led to a 26.4% surge in operating income. Further, its efforts to expand sales force and provide value-added services resulted in an improved growth profile.

The company also resorts to inorganic route to fuel growth in a highly fragmented and competitive market. The latest buyout of Prescription Containers is expected to be immediately accretive for MWI Vet.

Evidently, MWI Vet’s business is fully based on its relationship with vendors. Thus, any adverse changes in vendor rebates might negatively impact the company. Going forward, its growth will largely depend on obtaining favorable terms from its vendors. While macroeconomic uncertainty and volatile commodity prices remain a cause of concern, management is also wary that the recent drought might adversely affect fiscal 2013 results.

In addition, competitive landscape remains tough and consolidation by competitors could result in a tussle for market share. Thus, we prefer to remain on the sidelines for MWI Vet.

On the other hand, we look forward to other healthcare stocks such as Henry Schein (HSIC - Analyst Report), The Cooper Companies (COO - Analyst Report) and Conceptus . These stocks carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%